- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Redwood City Today
By the People, for the People
Exicure Announces Proposed Settlement of Stockholder Derivative Lawsuits
Clinical-stage biotech company resolves legal disputes with shareholders
Apr. 2, 2026 at 9:17pm
Got story updates? Submit your updates here. ›
The proposed settlement of stockholder lawsuits against Exicure allows the biotech company to move forward without the distraction of ongoing legal disputes.Redwood City TodayExicure, Inc., a clinical-stage biotechnology company focused on developing treatments for hematologic diseases, has announced a proposed settlement of several stockholder derivative lawsuits filed against the company and its executives. The settlement, if approved, would resolve the legal disputes and allow Exicure to move forward without the distraction of ongoing litigation.
Why it matters
Stockholder derivative lawsuits can be a significant distraction and drain on resources for public companies, especially smaller biotechs like Exicure that are focused on advancing their drug pipelines. The proposed settlement allows Exicure to put this legal matter behind it and concentrate on its core business of developing innovative therapies for blood disorders.
The details
The lawsuits were filed by certain Exicure stockholders and alleged breaches of fiduciary duty by the company's directors and officers. As part of the proposed settlement, Exicure has agreed to implement certain corporate governance reforms and make changes to its board of directors, but the company does not admit to any wrongdoing. The settlement is subject to approval by the court overseeing the case.
- The lawsuits were filed against Exicure in 2025.
- Exicure announced the proposed settlement on April 2, 2026.
The players
Exicure, Inc.
A clinical-stage biotechnology company developing therapeutics for hematologic diseases.
What’s next
The proposed settlement must be approved by the court before it can be finalized.
The takeaway
The resolution of these stockholder lawsuits allows Exicure to move forward and focus on advancing its drug pipeline without the distraction and expense of ongoing litigation, which is a positive development for the company and its shareholders.
